文献速递糖尿病

妊娠期2型糖尿病使用GLP-1受体激动剂及其他新型降糖药的安全性:法国全国性人群研究

Safety of glucagon-like peptide-1 receptor agonists and other new-generation glucose-lowering agents for the management of type 2 diabetes in pregnancy: a French nationwide population-based study.
PubMed 文献 · Diabetologia · 2026-09-29

该研究基于法国国家健康数据系统,纳入2011年1月至2024年8月期间19,092例孕前接受药物治疗的2型糖尿病孕妇的单胎妊娠,评估孕早期暴露于二线降糖药(包括GLP-1受体激动剂)与主要先天畸形的关联。与单用胰岛素相比,孕早期暴露于二线降糖药未增加总体或器官特异性主要先天畸形的风险,但敏感性分析提示GLP-1受体激动剂和磺脲类可能小幅增加心脏畸形风险。

要点

  • 孕早期暴露于二线降糖药未显著增加主要先天畸形风险。
  • GLP-1受体激动剂和磺脲类可能小幅增加心脏畸形风险,致畸性不能排除。
  • 研究未发现其他新型降糖药与总体畸形风险升高相关。

核心结论

  • 与单用胰岛素相比,孕早期暴露于二线降糖药未增加总体或器官特异性主要先天畸形风险。
  • 但GLP-1受体激动剂和磺脲类可能小幅增加心脏畸形风险,致畸性不能排除。

研究设计与样本

  • 基于法国国家健康数据系统的全国性人群队列研究。
  • 纳入2011年1月至2024年8月期间19,092例孕前药物治疗的2型糖尿病孕妇的单胎妊娠(孕周>22周)。
  • 孕早期暴露定义为受孕前30天至受孕后91天内至少配药一次。

主要发现

  • 17.5%的妊娠仅暴露于胰岛素,34.7%暴露于至少一种二线降糖药,10.4%未暴露于任何降糖药。
  • 与单用胰岛素相比,孕早期暴露于二线降糖药未增加总体或器官特异性主要先天畸形风险。
  • 敏感性分析采用更严格暴露定义时,GLP-1受体激动剂和磺脲类暴露后心脏畸形风险可能小幅增加。

临床怎么用

  • 临床中对孕前2型糖尿病女性使用二线降糖药(尤其是GLP-1受体激动剂和磺脲类)需权衡潜在心脏畸形风险。
  • 孕早期应优先考虑胰岛素治疗,二线降糖药的安全性数据仍需进一步积累。

局限性

  • 数据库缺乏BMI和HbA1c值,使用糖尿病严重程度代理变量进行混杂调整。
  • 敏感性分析提示GLP-1受体激动剂和磺脲类的心脏畸形风险不能排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and other second-line glucose-lowering agents are increasingly used among women of reproductive age. Data on the safety of these medications in pregnancy are limited. We aimed to assess the comparative safety of first-trimester exposure to second-line glucose-lowering agents on the risk of organ-specific congenital malformations among pregnancies affected by type 2 diabetes mellitus that was pharmacologically treated. METHODS: We conducted a population-based cohort study using the French National Health Data System including singleton infants born after pregnancies lasting more than 22 weeks, in women aged 18 to 50 years with pregestational, pharmacologically treated type 2 diabetes from January 2011 to August 2024. We defined first-trimester exposure to glucose-lowering agents as having at least one prescription filled from 30 days before through to 91 days after conception. All glucose-lowering agents were considered: insulin, metformin, GLP-1RA, sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), sulfonylureas and other glucose-lowering agents. The primary reference group was the use of insulin alone, but the use of metformin, with and without insulin, and non-use of glucose-lowering agents were also comparators in additional analyses to facilitate comparison with previous studies. Analysed outcomes were major congenital malformations during the delivery stay and up to 1 year after birth to consider delayed identification, using ICD-10 codes as per EUROCAT (European surveillance of congenital anomalies) guidelines. Adjusted RRs and 95% CIs were estimated using Poisson regressions with generalised estimating equations. Values of BMI and HbA1c were unavailable in the database; proxies of diabetes severity were used instead for confounding adjustment. RESULTS: Among 19,092 eligible pregnancies, 17.5% were exposed to insulin alone, 34.7% to at least one second-line glucose-lowering agent and 10.4% were unexposed to any glucose-lowering agent during the first trimester. Compared with insulin-only use, first-trimester exposure to second-line glucose-lowering agents was not associated with an increased risk of overall or organ-specific major congenital malformations. Sensitivity analyses using stricter exposure definitions suggested a possible small increased risk of cardiac malformations following first-trimester exposure to GLP-1 RA and sulfonylureas. CONCLUSIONS/INTERPRETATION: In this largest study to date on the use of glucose-lowering agents in pregnancy, first-trimester exposure to second-line glucose-lowering agents was not associated with an increased risk of major congenital malformations when compared with insulin-only use. However, a small increased risk of cardiac defects associated with first-trimester exposure to GLP-1RA and sulfonylureas is possible, and thus teratogenicity cannot be excluded.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Collier M, Chouchana L, Kaguelidou F, et al. Safety of glucagon-like peptide-1 receptor agonists and other new-generation glucose-lowering agents for the management of type 2 diabetes in pregnancy: a French nationwide population-based study. Diabetologia. 2026. PMID: 42809004. doi:10.1007/s00125-026-06882-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。